Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 179Urinary Bladder Neoplasms 31Carcinoma, Renal Cell 19Kidney Neoplasms 18Breast Neoplasms 13Wilms Tumor 11Neoplasms 10Neoplasm Metastasis 10Lung Neoplasms 9Testicular Neoplasms 8Testicular Germ Cell Tumor 6Melanoma 6Carcinoma, Non-Small-Cell Lung 6Non-Muscle Invasive Bladder Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Endometrial Neoplasms 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Vaginal Neoplasms 4Uterine Cervical Neoplasms 4Urethral Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Seminoma 4Sarcoma 4Recurrence 4Rectal Neoplasms 4Radiation Injuries 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Urothelial Carcinoma × Radiotherapy × Genitourinary × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡